Business Description
Genflow Biosciences PLC
ISIN : GB00BP2C3V08
Total Employee Number:
5Description
Genflow Biosciences PLC is a preclinical biotechnology company focused on the development of biological interventions (namely gene therapies) which are aimed at tackling the effects of aging, potentially slowing or halting the aging process and so reducing the incidence of age-related diseases and thereby increasing health span. Its flagship compound, GF-1002, is based on the delivery of a variant of the SIRT6 gene and is currently in preclinical development.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | -1.22 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 15.7 | |||||
3-Year EPS without NRI Growth Rate | 15.7 | |||||
3-Year FCF Growth Rate | 15.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 14.81 | |||||
9-Day RSI | 28.59 | |||||
14-Day RSI | 35.78 | |||||
3-1 Month Momentum % | 20.67 | |||||
6-1 Month Momentum % | 0.56 | |||||
12-1 Month Momentum % | 217.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.45 | |||||
Quick Ratio | 0.45 | |||||
Cash Ratio | 0.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -19.1 | |||||
Shareholder Yield % | -11.41 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -325.73 | |||||
ROIC % | -561.21 | |||||
3-Year ROIIC % | -48.54 | |||||
ROC (Joel Greenblatt) % | -85080 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -8.01 | |||||
EV-to-EBITDA | -8.02 | |||||
EV-to-FCF | -7.9 | |||||
Earnings Yield (Greenblatt) % | -12.48 | |||||
FCF Yield % | -12.53 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:GENFF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Genflow Biosciences PLC Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.005 | ||
| Beta | 0.7625 | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 140.62 | ||
| 14-Day RSI | 35.78 | ||
| 14-Day ATR ($) | 0.003049 | ||
| 20-Day SMA ($) | 0.030675 | ||
| 12-1 Month Momentum % | 217.54 | ||
| 52-Week Range ($) | 0.01 - 0.0711 | ||
| Shares Outstanding (Mil) | 566.41 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Genflow Biosciences PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Genflow Biosciences PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-09-30 | In 95 days | ||
| General meeting for 2026 | 2026-06-29 10:00 | In 3 days | ||
| Annual report for 2025 | 2026-04-30 | 0.04 (-5.88%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-30 | 0.04 (-5.88%) | ||
| Second quarter earnings results for 2025 | 2025-09-30 | 0.03 (+0.00%) | ||
| General meeting for 2025 | 2025-06-12 09:00 | 0.02 (+0.00%) | ||
| Annual report for 2024 | 2025-04-30 | 0.03 (+0.00%) | ||
| Fourth quarter earnings results for 2024 | 2025-04-30 | 0.03 (+0.00%) | ||
| Second quarter earnings results for 2024 | 2024-09-30 | 0.03 (+0.00%) | ||
| General meeting for 2023 | 2024-06-27 12:00 | 0.02 (+0.00%) |
Show
Entries
Genflow Biosciences PLC Frequently Asked Questions
What is Genflow Biosciences PLC(GENFF)'s stock price today?
The current price of GENFF is $0.02. The 52 week high of GENFF is $0.07 and 52 week low is $0.01.
When is next earnings date of Genflow Biosciences PLC(GENFF)?
The next earnings date of Genflow Biosciences PLC(GENFF) is 2026-09-30 Est..
Does Genflow Biosciences PLC(GENFF) pay dividends? If so, how much?
Genflow Biosciences PLC(GENFF) does not pay dividend.
Guru Commentaries on OTCPK:GENFF
No articles.
Press Release
Articles on Genflow Biosciences PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers